trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['pan-tumor']
awesome presentation by dr funda meric bernstam of destiny pan-tumor-02
orr
ihc 3+ 61.3%
ihc 2+ 27.2%
her-2 may be another agnostic target #asco23 
Chief of GU Cancer @oncoclinicas Scientific Director GU tumors @Lacog_group